Set Your Location to See Relevant Information

Setting your location helps us to show you nearby providers and locations based on your healthcare needs.

ATH-1017-AD-0202

Objective
Description

EvergreenHealth Neuroscience Institute is conducting a phase 2, randomized, placebo-controlled study to evaluate if a new investigational drug is safe and effective in improving symptoms of mild to moderate Alzheimer’s disease.

Currently enrolling
Who may be eligible to participate?
  • Between 55 to 85 years of age
  • Have been diagnosed with mild to moderate Alzheimer’s disease
  • Have a reliable support person or caregiver willing to participate in study visits, report on daily activities, and oversee or help with treatment administration.

Other inclusion/exclusion criteria apply.

What does participation involve?

Total participation in this study will be approximately 8 months. This includes:

  • a Screening Period of up to 28 days
  • a Pre-baseline Period (to perform an initial assessment of a subject’s condition) of up to 5 days;
  • a Treatment Period, including Baseline (where subjects will receive their assigned study medication) of up to 26 weeks (approximately 6 months). Investigational drug will be administered by subcutaneous (SC) injection once-daily; an
  • a Post-treatment Follow-up Period (to check subjects’ overall health) of 4 weeks.
Investigator

Daniel J. Burdick, MD

Clinical Trial Categories

  • Alzheimer's Disease
Contact
EvergreenHealth Research Services at 425-899-5385
or EvergreenResearch@evergreenhealth.com

Contact Us

Call us at (425) 899-5385 or use our online information request form.

Online Form